奇正藏藥(002287.SZ)業績快報:上半年淨利升346.92%至9.89億元
格隆匯7月27日丨奇正藏藥(002287.SZ)披露2021年半年度業績快報,報吿期內,公司實現營業收入7.81億元,同比增長27.69%,其中藥品業務同比增長27.21%;營業利潤10.89億元,同比增長316.08%;歸屬於上市公司股東淨利潤9.89億元,同比增長346.92%;基本每股收益1.8712元。
公司2021年半年度業績較上年同期增加的主要原因為:百洋醫藥(301015.SZ)上市後,公司參與設立的併購基金羣英投資以公開市場的價格確認公允價值變動損益增加收益,公司對此投資按照權益法進行核算,投資收益確認增加,該事項屬於非經常性損益。同時,由於羣英投資公允價值變動損益受百洋醫藥二級市場股價波動影響較大,可能會導致公司業績存在一定的波動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.